Toxicology in Vitro

Toxicology in Vitro is an international Elsevier journal founded in 1987 that publishes research papers, reviews and workshop reports on in vitro and in silico systems for toxicological evaluation, collectively known as New Approach Methodologies, is the official journal of the European Society of Toxicology In Vitro, and has a 2025 impact factor of 2.7Toxicology in Vitro（《体外毒理学》）是 Elsevier 于 1987 年创办的国际期刊，刊载体外与计算机模拟系统用于毒理学评价（统称新方法学）的研究论文、综述与研讨会报告，是欧洲体外毒理学会的官方期刊，2025 年影响因子为 2.7。

Scope

• It publishes original research papers, reviews and workshop reports focusing on the application and use of in vitro and in silico systems for toxicological evaluations, collectively described as New Approach Methodologies刊载聚焦体外与计算机模拟系统用于毒理学评价的原创研究论文、综述与研讨会报告，统称新方法学。
• This includes the utilisation or development of New Approach Methodologies for assessing the potential adverse effects of chemicals for human safety assessment涵盖运用或开发新方法学以评估化学物对人体安全的潜在不良作用。
• In vitro techniques include primary cells, tissue slices, cell lines and stem cells such as adult, embryonic and induced pluripotent cells, or subcellular preparations of them体外技术包括原代细胞、组织切片、细胞系与干细胞（成体、胚胎与诱导多能干细胞）及其亚细胞制备物。
• The journal strongly supports the reduction, refinement and replacement of animals in toxicology evaluations, known as the 3Rs该刊强力支持毒理学评价中动物实验的减少、优化与替代，即 3R 原则。
• Authors are strongly encouraged to use normal non-transformed human cells, report STR profiles, open their raw data, characterise their models, use animal-product-free materials, describe detailed methods with appropriate statistics, report the source and lot number of test substances, and quantify compound kinetics over time强烈鼓励使用正常非转化人源细胞、报告 STR 谱、开放原始数据、充分表征模型、使用无动物成分材料、详述方法与恰当统计、报告受试物来源与批号，并随时间定量化合物动力学。
• It does not accept purely in vivo studies and rarely accepts papers mixing animal and in vitro work, and it discourages unidentified mixtures, purely pharmacological studies, non-human cells where a human equivalent exists, and cytotoxicity reports without mechanistic support不接受纯体内研究，极少接收动物与体外混合的论文，且不鼓励未鉴定混合物、纯药理学研究、在存在人类等效细胞时仍用非人细胞，以及缺少机制支撑的细胞毒性报告。

History

• It was founded in 1987 by Pergamon Press in Oxford and New York and published in association with BIBRA, the British Industrial Biological Research Association, with volume 1, number 1 appearing in 1987该刊 1987 年由 Pergamon Press 在牛津与纽约创办，并与英国工业生物学研究协会 BIBRA 联合出版，第一卷第一期于 1987 年出版。
• The founding volume carried the lead editorial signed by Iain F.H. Purchase and Gordon C. Hard and the first research paper, on structure-activity relationship models built with the neutral red cytotoxicity assay创刊卷载有由 Iain F.H. Purchase 与 Gordon C. Hard 署名的创刊社论，以及首篇研究论文，即以中性红细胞毒性试验建立构效关系模型一文。^[1][2]
• Iain F.H. Purchase was the founding editor in 1987 and served as editor in chief until 1994Iain F.H. Purchase 为 1987 年创刊主编，并任主编至 1994 年。^[3]
• The journal name has never changed, and the publisher lineage runs from Pergamon Press from 1987 to 1991, through the 1991 acquisition of Pergamon by Elsevier, to Elsevier Ltd. today该刊刊名自创刊至今未变，出版方沿革为 1987 至 1991 年的 Pergamon Press，经 1991 年 Pergamon 并入 Elsevier，至今为 Elsevier Ltd.。
• It is now the official journal of the European Society of Toxicology In Vitro, and the founding association with BIBRA is historical, as current Elsevier pages no longer mention BIBRA该刊现为欧洲体外毒理学会的官方期刊，创刊期与 BIBRA 的联合关系已成历史，现行 Elsevier 页面已不再提及 BIBRA。
• It now publishes volumes at roughly a monthly rate while NLM historically recorded six issues a year, and it is subscription based with a gold open access option at an article processing charge of USD 3,940, with a 2025 impact factor of 2.7 and a CiteScore of 5.7现出版卷频接近每月一卷，NLM 历史刊期记为每年六期，订阅制并含金色开放获取选项，版面费 3940 美元，2025 年影响因子 2.7，CiteScore 5.7。

Editors

• The editor in chief is Paul Jennings, professor at the Division of Molecular and Computational Toxicology of Vrije Universiteit Amsterdam in the Netherlands现任主编为 Paul Jennings，荷兰阿姆斯特丹自由大学分子与计算毒理学部教授。
• The six associate editors are Maxime Culot of Artois University in France, Julio Davila in Florida in the United States, Martin Leonard of the UK Health Security Agency in London, Helena Kandarova of the Centre of Experimental Medicine of the Slovak Academy of Sciences in Bratislava, Ilka Maschmeyer of TissUse GmbH in Berlin and Anja Wilmes of Vrije Universiteit Amsterdam六位副编辑为法国阿尔图瓦大学的 Maxime Culot、美国佛罗里达的 Julio Davila、英国伦敦卫生安全局的 Martin Leonard、斯洛伐克布拉迪斯拉发斯洛伐克科学院实验医学中心的 Helena Kandarova、德国柏林 TissUse 公司的 Ilka Maschmeyer 与阿姆斯特丹自由大学的 Anja Wilmes。
• The editorial board has about 35 editors and board members from 12 countries, led by the United States with 12, the Netherlands with 6 and Germany with 4编委会约 35 位编辑与编委，分布于 12 个国家与地区，其中美国 12 位、荷兰 6 位、德国 4 位居前三。
• The international editorial board includes Daniel Acosta, Gáspár Bánfalvi, Bas J. Blaauboer, Brian Chorley of the US EPA, Marion Ehrich, Mary Beth Genter, Sebastian Hoffmann, Ivonne Rietjens, Remco Westerink and Xiaozhong Yu, among others国际编委包括 Daniel Acosta、（Gáspár Bánfalvi）、Bas J. Blaauboer、美国环保署的 Brian Chorley、Marion Ehrich、Mary Beth Genter、Sebastian Hoffmann、Ivonne Rietjens、Remco Westerink 与 Xiaozhong Yu 等。
• Manuscripts are submitted through Elsevier Editorial Manager at editorialmanager.com/TIV and are peer reviewed, with 5 days from submission to first decision, 61 days to a decision after review, 120 days from submission to acceptance and 3 days from acceptance to online publication稿件经 Elsevier Editorial Manager（editorialmanager.com/TIV）投稿并同行评审，投稿到首次决定 5 天、送审后决定 61 天、投稿到录用 120 天、录用到在线发表 3 天。
• The journal uses Your Paper Your Way for initial submissions and requires declarations of competing interests, generative artificial intelligence use and research data policy, while correspondence and hot topics and debates are handled directly by the editor in chief, and results of the biennial ESTIV Congress are often published as special issues该刊初投采用 Your Paper Your Way，并要求声明利益冲突、生成式人工智能使用与研究数据政策；通讯与热点及辩论由主编直接处理，每两年一届的 ESTIV 大会成果常以专刊形式出版。